share_log
下载App
扫码立即下载
  • 下载App

    扫码立即下载

+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

Reynders McVeigh Capital Management LLC Has $10.61 Million Stock Position in Novartis AG (NYSE:NVS)

Reynders McVeigh Capital Management LLC 在诺华股份公司(纽约证券交易所代码:NVS)持有 1,061 万美元的股票头寸

Financial News Live ·  02/03 03:32

Reynders McVeigh Capital Management LLC grew its position in Novartis AG (NYSE:NVS – Get Rating) by 1.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 139,608 shares of the company's stock after buying an additional 2,387 shares during the period. Reynders McVeigh Capital Management LLC's holdings in Novartis were worth $10,612,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Activest Wealth Management acquired a new position in shares of Novartis in the 3rd quarter valued at $26,000. Carolinas Wealth Consulting LLC lifted its position in Novartis by 146.7% in the 2nd quarter. Carolinas Wealth Consulting LLC now owns 370 shares of the company's stock valued at $31,000 after acquiring an additional 220 shares in the last quarter. Creative Financial Designs Inc. ADV lifted its position in Novartis by 42.7% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 441 shares of the company's stock valued at $34,000 after acquiring an additional 132 shares in the last quarter. Curi Wealth Management LLC bought a new stake in Novartis in the 2nd quarter valued at $46,000. Finally, Adirondack Trust Co. lifted its position in Novartis by 327.7% in the 3rd quarter. Adirondack Trust Co. now owns 556 shares of the company's stock valued at $42,000 after acquiring an additional 426 shares in the last quarter. Institutional investors and hedge funds own 8.12% of the company's stock.

Get Novartis alerts:

Novartis Stock Performance

NYSE:NVS traded down $2.33 during mid-day trading on Thursday, reaching $85.90. 385,656 shares of the company's stock were exchanged, compared to its average volume of 2,160,289. Novartis AG has a one year low of $74.09 and a one year high of $94.26. The firm has a market capitalization of $190.06 billion, a PE ratio of 9.07, a price-to-earnings-growth ratio of 2.17 and a beta of 0.52. The business's fifty day simple moving average is $90.68 and its two-hundred day simple moving average is $84.76. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.07 and a current ratio of 1.31.

Analysts Set New Price Targets

Several equities research analysts have commented on NVS shares. Barclays cut their price target on shares of Novartis from CHF 85 to CHF 75 in a research report on Friday, October 14th. StockNews.com started coverage on shares of Novartis in a research report on Wednesday, October 12th. They set a "strong-buy" rating on the stock. UBS Group boosted their price target on shares of Novartis from CHF 82 to CHF 84 and gave the stock a "neutral" rating in a research report on Wednesday, December 14th. Stifel Nicolaus raised shares of Novartis from a "hold" rating to a "buy" rating in a research report on Monday, December 5th. Finally, Morgan Stanley lowered shares of Novartis from an "equal weight" rating to an "underweight" rating in a research note on Friday, January 6th. Three analysts have rated the stock with a sell rating, seven have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $85.11.

About Novartis

(Get Rating)

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals.

Read More

  • Get a free copy of the StockNews.com research report on Novartis (NVS)
  • The Bottom Is In For Meta Platforms, Volatility Is Not Over
  • Analyzing Alaska Air's Recent Earnings
  • Apple's Earnings, Expectations and Surprises
  • T-Mobile Delivers Where it Matters Most to Investors
  • Exxon Mobil Could Gush To New Highs Very Soon

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Get Rating).

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。